品类扩张的成本真实存在，大多不可见，最终由原本支付所有费用的合同承担。 这个问题在医疗机构中的版本并非通用版本。已在38,000个生命上承担下行风险，却缺乏episode成本数据来定价——因此忽略episode成本的答案必然错误。分析必须从支付方组合和面板规模开始，而非从收入开始。
品类扩张的成本真实存在，大多不可见，最终由原本支付所有费用的合同承担。 这个问题在医疗机构中的版本并非通用版本。已在38,000个生命上承担下行风险，却缺乏episode成本数据来定价——因此忽略episode成本的答案必然错误。分析必须从支付方组合和面板规模开始，而非从收入开始。
服务线和基于价值的合同不断积累，因为每项新增都有单独理由，且从未移除。成本不在其中任何一项，而在于它们共同造成的复杂性——提供者日程、协议差异、计费知识、预测错误。
这些成本由盈利的核心不成比例地承担，因为那里是被分割的产能所在。这就是为什么精简往往能增加总利润，即使移除的线条名义上仍有贡献。
值得做的分析按提供者贡献对合同排序，对照其消耗的约束，然后询问尾部哪些有理由存在——战略支付方或面板要求——哪些只是因为没人查看。
这三者同时出现才是标志。单独一个通常指向其他问题。
✓ 少数合同占据了提供者贡献的大部分
✓ 数年内没有终止任何基于价值的合同
✓ episode成本上升速度快于面板规模
通常会让情况更糟的做法。 仅按归因生命数削减尾部，这会移除容易承担的合同，并保留那些悄无声息消耗提供者产能却无episode成本数据的合同。
It is for you if you run or finance a healthcare provider and a minority of lines produces the large majority of revenue. It is the situation where the numbers are available but nobody has put them in an order that produces a decision.
It is not for you if Percision is the wrong tool if you already know the answer and only need execution capacity, or if the business is pre-revenue — then the constraint is evidence about the market, not analysis of your own figures. Percision is not a lawyer, tax advisor, auditor, licensed appraiser, clinical or regulatory filer, or an AI implementation shop. It does not do HR casework, creative-only brand work, or impersonate a named consulting firm. It is a strategy analysis engine — not a template library. Also wrong if you need facilitation, politics, or someone to sit with a lender or buyer. Those are human jobs.
Percision is not a lawyer, tax advisor, auditor, licensed appraiser, clinical or regulatory filer, or an AI implementation shop. It does not do HR casework, creative-only brand work, or impersonate a named consulting firm. It is a strategy analysis engine — not a template library.
Below is an excerpt from a real run of this analysis on 一家医疗机构. It is a sample profile rather than a customer, and it is engine output translated from English — this is the format you get, on your own numbers.
The subject is Cedar Ridge Health Partners, a sample company profile used for testing rather than a customer — 38,000 attributed lives under value-based contracts.
Excerpt from a real Percision run · Pricing Strategy · sample company profile
The move. Turn 38,000 downside-risk lives into a self-funding 36-month analytics platform via payer co-development.
The leak it closes. Settlement lag (6–9 months) and payer audit adjustments reduced via internal attribution engine
The assumption it rests on. Payer agrees to 5-year exclusivity and 15–25% platform margin split — the engine put the probability at 0.75.
| Investment required | $2.5–3.0M over 18 months |
| Expected return | 7.6–9.1× over three years on $2.5–3.0M investment |
| Revenue, year 1 | $0 (platform build phase) |
| Revenue, year 2 | $6.9–11.4M (first shared-savings settlement) |
| Revenue, year 3 | $13.7–22.8M (full run-rate) |
| Exit criteria | Terminate if payer refuses exclusivity by Month 6 OR if attribution accuracy <80% by Month 18 OR if shared-savings pool < $60M by end of contract year 2 |
This is one move out of a full analysis. Read a complete report — every page, no email required.
This question routes to 矩阵策略, one of 29 engagements the platform runs. For 医疗机构 it works through cost per episode, payer mix, panel size and contribution per provider, then produces the sequence rather than a list of options — which move first, what it funds, and the observation that would say the sequence is wrong.
You watch the analysis get built before paying anything. 在此阅读完整报告 if you would rather see the depth first.
按绑定约束的单位贡献排序，然后检查战略依赖性。仅按收入排名在两个方向上都会出错。
有些会，分析应在决策前而非之后定价该风险。通常风险收入小于移除的复杂性成本，但这应是发现而非假设。
很少被追踪，这就是它增长的原因。可行的代理是单位产量的运营成本趋势；当产量上升而该成本上升时，复杂性通常是解释。
Materially, yes. Downside risk has been accepted on 38,000 lives without the cost-per-episode data needed to price it — which changes both the diagnosis and the order of the fixes. The metrics that decide it here are cost per episode, payer mix, panel size, and an answer built on industry-general benchmarks will usually point at the wrong one first.
Less than most people expect. Your last twelve months of revenue and cost split the way you already split it, plus whatever you hold on cost per episode and payer mix. The analysis is explicit about what it is assuming where your data stops, which is more useful than waiting for numbers you may never have.
Percision is the wrong tool if you already know the answer and only need execution capacity, or if the business is pre-revenue — then the constraint is evidence about the market, not analysis of your own figures. Percision is not a lawyer, tax advisor, auditor, licensed appraiser, clinical or regulatory filer, or an AI implementation shop. It does not do HR casework, creative-only brand work, or impersonate a named consulting firm. It is a strategy analysis engine — not a template library. Also wrong if you need facilitation, politics, or someone to sit with a lender or buyer. Those are human jobs.
Percision is not a lawyer, tax advisor, auditor, licensed appraiser, clinical or regulatory filer, or an AI implementation shop. It does not do HR casework, creative-only brand work, or impersonate a named consulting firm. It is a strategy analysis engine — not a template library.
Describe the situation in your own words and we will tell you which analysis answers it — before you sign up for anything.
Describe my situation →Prefer to skip ahead? Go straight to the free diagnostic.
English · Español · Deutsch · Português · Français · Italiano · Nederlands · 日本語 · 한국어 · 中文 · Polski · Svenska · Türkçe · العربية · Tiếng Việt · ไทย · हिन्दी · עברית